StockMarketWire.com - Tiziana Life Sciences said it had submitted an investigational new drug application to the US Food and Drug Administration.
It was submitted to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.
Foralumab was being developed for the treatment of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
At 8:57am: [LON:TILS] Tiziana Life Sciences Plc share price was +0.5p at 43.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.